CTCX (Carmell Corp.) Earnings per share for the last four quarters

Carmell Corp (CTCX) - corporate logo

Carmell Corporation (CTCX) is a reputable biopharmaceutical player developing safe regenerative materials for aesthetics. The annual EPS TTM growth rate reflects profit dynamics, with the current value standing at . Production relies on robotic tissue processing to minimize headcount. The company is currently focusing on internal biotechnology development and capital preservation for R&D, excluding merger and acquisition deals.

CTCX carmellrx.com Net earnings per share (EPS TTM) (07/04/2022 - 11/18/2026)

CTCX (Carmell Corporation): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:CTCX (Carmell Corp.)
Core merchandise of Carmell Therapeutics

This metric is calculated as the percentage change in trailing twelve-month (ttm) rolling annual earnings per share compared to the same period last year. It measures the dynamics of actual earnings, allowing for an assessment of the growth or decline in business efficiency. For Carmell Corporation (CTCX), with its early-stage biotech projects and lack of stable cash flow, this indicator is extremely volatile. Purchasing the asset at the peak of the net income per share YoY ttm chart risks overpayment.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Pluri Inc. - Net earnings per share for the last 12 months|Net earnings per share for the trailing year Synlogic Corp|LPCN - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Matinas BioPharma Holdings, Inc. MTNB|SPRB: Net earnings per share (EPS TTM)|Galecto Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS